



NCI SBIR Contracts Funding Webinar

October 30, 2013 3 – 4:30 pm EDT

For audio, dial in: 240.276.6338

Meeting ID: 735 583 026

For Technical Support, call 866-229-3239 and choose option 1

Agenda



Welcome Jennifer Shieh	3:00 pm
Overview of the NCI SBIR/STTR Programs Michael Weingarten	3:05 pm
What Does It Take to Get Awarded? Tips on Submitting a Proposal Michael Weingarten	3:15 pm
The Contracts Process at NCI: How are SBIR Contracts Different from Grants? Michael Weingarten	3:30 pm
Q&A	3:40 pm
FY2014 Contract Funding Opportunities at NCI Andrew Kurtz and Deepa Narayanan	3:50 pm
More Q&A	4:10 pm
Closing Remarks	4:25 pm

http://sbir.cancer.gov/funding/contracts



Contract Topic Details:

http://sbir.cancer.gov/funding/contracts

EXTENDED

Proposal Deadline:

November 25, 2013 at 4:30PM Eastern Time

Amendment published 10/25/13

http://grants.nih.gov/grants/guide/notice-files/NOT-OD-14-013.html

Submit Your Questions



Submit your questions any time via the Q&A box on the right-hand side of your screen.

If you do not see the Q&A box, you can expand it by hovering over the green bar at the top of your screen and clicking the Q&A

button.



Submit Your Questions



Please submit questions of a general nature, with no proprietary information.

We will not answer questions specific to your project in this webinar. Send your questions about:

CONTRACTS to Elizabeth Shanahan, eshanahan@mail.nih.gov or GRANTS to NCIsbir@mail.nih.gov

The webinar slides, audio recording, and Q&A will be published to the website, http://sbir.cancer.gov

Agenda



Welcome Jennifer Shieh	3:00 pm
Overview of the NCI SBIR/STTR Programs Michael Weingarten	3:05 pm
What Does It Take to Get Funded? Tips on Submitting a Proposal Michael Weingarten	3:15 pm
The Contracts Process at NCI: How are SBIR Contracts Different from Grants? Michael Weingarten	3:30 pm
Q&A	3:40 pm
FY2014 Contract Funding Opportunities at NCI Andrew Kurtz and Deepa Narayanan	3:50 pm
More Q&A	4:10 pm
Closing Remarks	4:25 pm

http://sbir.cancer.gov/funding/contracts



Small Business Innovation Research (SBIR)

Set-aside program for small business concerns to engage in Federal R&D with the potential for commercialization Federal agencies with an extramural R&D budget > \$100M **Set Aside** (FY14)

2.8%

Small Business Technology Transfer (STTR)

Set-aside program to facilitate cooperative R&D between small business concerns and U.S. research institutions with the potential for commercialization

0.40%

Federal agencies with an extramural R&D budget > \$1B

~\$700M annually at NIH ~\$110M annually at NCI

No audio? Dial 240.276.6338 Meeting ID: 735 583 026

Reasons to Seek SBIR/STTR Funding



Provides seed funding for innovative technology development

Not a Loan

No repayment is required

Doesn't impact stock or shares in any way (i.e., non-dilutive)

- Intellectual property rights retained by the small business
- Provides recognition, verification, and visibility
- Helps provide leverage in attracting additional funding or support (e.g., venture capital, strategic partner)

SBIR & STTR: Three-Phase Program



- Proof-of-Concept study
- \$150,000 over 6 months (SBIR) or 1 year (STTR)

- Commercialization stage
- Use of non-SBIR/STTR funds

Phase I Phase II
Fast-Track Application
Combined Phase I & II

Phase III COMMERCIALIZATION

- Research & Development
- Commercialization plan required
- \$1 million over 2 years

* Hard caps on award sizes: \$225,000 for Phase I; \$1.5 million for Phase II

Note: Actual funding levels may vary by topic.

NCI SBIR Phase IIB Bridge Award



Phase I FEASIBILITY

Phase II
DEVELOPMENT

NCI SBIR Phase IIB Bridge Award

CROSSING THE VALLEY OF DEATH

Phase III COMMERCIALIZATION

- Provides up to \$1M per year for up to 3 years
- Open to any NIH-funded Phase II awardees with projects relevant to NCI mission
- Accelerates commercialization by incentivizing partnerships with third-party investors & strategic partners <u>earlier in the</u> <u>development process</u>
- Competitive preference and funding priority to applicants that can raise substantial third-party funds (i.e., ≥ 1:1 match)

SBIR Eligibility Requirements

New Rules starting 1/28/13



- Applicant is a Small Business Concern (SBC)
- Organized for-profit U.S. business
- 500 or fewer employees, including affiliates
- Pl's primary employment (>50%) must be with the SBC at time of award & for duration of project
- > 50% U.S.- owned by individuals and independently operated*

OR

- > 50% owned and controlled by other business concern/s that is/are
 - > 50% owned and controlled by one or more individuals*

OR

 > 50% owned by <u>multiple</u> venture capital operating companies, hedge funds, private equity firms, or any combination of these *

^{*}Formerly >= 51%; *New rule starting 1/28/13, **NIH SBIR only**

STTR Eligibility Requirements



- Applicant is a Small Business Concern (SBC)
- Organized for-profit U.S. business
- Formal cooperative R&D effort
 - Minimum 40% by small business
 - Minimum 30% by US research institution
- US Research Institution: college or university; non-profit research organization; Federally-Funded R&D Center (FFRDC)
- Principal Investigator's primary employment may be with either the SBC or the research institution
- SBC must have right to IP to carry out follow-on R&D and commercialization



	SBIR	STTR
Research Partner	Permits partnering Small business must do 67% Phase I, 50% Phase II	Requires partnering with US research institution Small business min. 40%, Research institution min. 30%
Principal Investigator	Primary employment must be with small business	PI may be employed by either small business or research institution, and must commit minimum of 10% effort to project

Small Business Concern is **ALWAYS** Applicant/Awardee Organization





The NIH SBIR/STTR Programs


http://sbir.nih.gov



NIH = 27 Institutes & Centers

24 Participants in the SBIR/STTR Program





Multiple Funding Solicitations Know the Application Deadlines



SBIR & STTR Omnibus Solicitations for **Grant Applications**

Release: January

Receipt Dates: April 5, August 5, and December 5

See the NIH Guide for other Program Announcements (PA's) and Requests for Application (RFA's), i.e. grants

Release: Weekly

Receipt Dates: Various

Solicitation of the NIH & CDC for SBIR Contract Proposals

Release: August – sign up for the email list to get notified!

Receipt Date: November 25

http://grants.nih.gov/grants/guide



http://sbir.cancer.gov





The NCI SBIR Development Center

http://sbir.cancer.gov



NCI SBIR Development Center Program Directors





Michael Weingarten, MA **Director** NCI SBIR Development Center



Greg Evans, PhD **Lead Program Director** Cancer Biology, E-Health, Epidemiology, Research Tools



Andrew J. Kurtz, PhD **Lead Program Director** Biologics, Small Molecules, Nanotherapeutics, Molecular Diagnostics, Bridge Award



Patricia Weber, DrPH **Program Director** Digital Health, Therapeutics, Biologics, SBIR Investor Forum, FRAC Workshop



Program Director In-Vitro Diagnostics, Theranostics, early-stage drug development, Bioinformatics, FRAC Workshop

Todd Haim, PhD **Program Director**

Jian Lou, PhD



Deepa Narayanan, MS **Program Director** Cancer Imaging, Clinical Trials, Radiation Therapy, SBIR Investor Forum, FRAC Workshop



Small Molecules, Biologics, Immunotherapeutics, Theranostic

Amir Rahbar, PhD, MBA

Program Director



s. SBIR Investor Forum, FRAC Workshop



In-Vitro Diagnostics, Biologics, Therapeutics, Proteomics, SBIR Investor Forum



Jennifer Shieh, PhD **Program Director**


Digital Health, Bioinformatics, Evaluation, SBIR Investor Forum, FRAC Workshop



Ming Zhao, PhD **Program Director** Cancer Diagnostics & Therapeutics, Cancer Control & Prevention, Molecular Imaging, Bioinformatics, Stem Cells

Pipeline of 400+ vetted projects





NCI SBIR Investor Forum



Exclusive opportunity for some of the most promising NCI-funded companies to showcase their technologies

http://sbir.cancer.gov/investorforum/



- In 2012, 18 top SBIR-funded companies presented
- Over 200 life science investors & leaders
- 150+ one-on-one meetings
- 2010 Investor Forum: 8 out of 14 presenting companies closed deals collectively valued at over \$230M

Workshop on Federal Resources to Accelerate Commercialization



Bringing together NCI SBIR/STTR awardees to move funded technologies from bench to bedside

http://sbir.cancer.gov/FRACWorkshop

- May 7, 2013 at NCI Shady Grove
- Speakers from FDA, CMS, USPTO, and White House OSTP
- Panels on other sources of federal funding, resources & collaborative programs at NIH, and unique life science investment organizations
- One-on-one meetings with program directors and speakers

Agenda



	Welcome Jennifer Shieh	3:00 pm
	Overview of the NCI SBIR/STTR Programs Michael Weingarten	3:05 pm
	What Does It Take to Get Awarded? Tips on Submitting a Proposal Michael Weingarten	3:15 pm
	The Contracts Process at NCI: How are SBIR Contracts Different from Grants? Michael Weingarten	
	Q&A	3:40 pm
	FY2014 Contract Funding Opportunities at NCI Andrew Kurtz and Deepa Narayanan	3:50 pm
	More Q&A	4:10 pm
	Closing Remarks	4:25 pm
http://sbi	r.cancer.gov/funding/contracts	




What Does It Take to Get Awarded?

Tips on Submitting a Contract Proposal



The Contracts Proposal Process





Read the Solicitation



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS), THE NATIONAL INSTITUTES OF HEALTH (NIH) AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) SMALL BUSINESS INNOVATIVE RESEARCH (SBIR) PROGRAM

PROGRAM SOLICITATION PHS 2014-1

Closing Date: November 13, 2013, 4:30PM Eastern Time

Participating HHS Components:

- The National Institutes of Health (NIH)
- The Centers for Disease Control and Prevention (CDC)

IMPORTANT

Deadline for Receipt: Proposals must be submitted by November 13, 2013, 4:30PM Eastern Time

Solicitation Changes:

As a result of program reauthorization, the solicitation has been EXTENSIVELY rewritten and follows the changes of the SBIR/STTR reauthorization. Please read the entire solicitation carefully prior to submitting your proposal.

Please go to http://www.sbir.gov/about/sbir-policy-directive to read the SBIR/STTR Policy Directive issued by the Small Business Administration.

http://grants.nih.gov/grants/funding/SBIRContract/PHS2014-1.pdf

Read the Amendment too!

http://grants.nih.gov/grants/guide/notice-files/NOT-OD-14-013.html

Deciding to Submit a Proposal



- Your project fits the contract topic description
- You can achieve the specified milestones & deliverables
- Innovative solution to significant unmet clinical need
- Significant commercial potential
- Leverages company/founder expertise
- Need funding to produce feasibility data
- Need funding for development
- Start-up: Too early for private investment
- Established SBC: No resources to try new approach, but board supports SBIR

When NOT to Submit a Proposal



- Chasing solicitations "why not?"
- Chasing "cool" technologies
- Need cash urgently
 - SBIRs take 8-16 months or more to get and you must start with Phase I (~\$225K)
- Incremental upgrade: no change to clinical paradigm
- "Me too" product matching competitor's capabilities
- Basic research still required to demonstrate commercial and clinical feasibility

Key Tips for Submitting a Proposal



- Start when the solicitation is released
 - Read the solicitation!
- Take care of the administrative registrations
 - DUNS
 - SAM.gov
 - SBA Company Registry (http://sbir.gov/registration)

Key Tips for Submitting a Proposal



- Build the right team
 - Partner to fill gaps
 - Get letters of support (not required but can be helpful)
- Reviewers only see the proposal
 - How does your proposal fit with the contract topic?
 - What is the problem you are uniquely able to solve?
 - Why is this approach innovative?
 - What is the potential for commercialization?
- Run your own "peer review"
 - Read your material critically as if you were the reviewer; ask collaborators to review the proposal

Before You Write a Contract Proposal or Grant Application




- Review similar, currently funded NIH projects
 - NIH Project RePORTER, http://projectreporter.nih.gov/
- For contracts, send your questions to Elizabeth Shanahan, <u>eshanahan@mail.nih.gov</u>
- For grants, contact NCI Program Director in advance (at least 1 month before due date!) to discuss your specific aims and receive feedback
 - NCIsbir@mail.nih.gov
 - http://sbir.cancer.gov/contact_us.asp

Search Previous Awards



http://projectreporter.nih.gov



Agenda



Welcome Jennifer Shieh	3:00 pm
Overview of the NCI SBIR/STTR Programs Michael Weingarten	3:05 pm
What Does It Take to Get Awarded? Tips on Submitting a Proposal Michael Weingarten	3:15 pm
The Contracts Process at NCI: How are SBIR Contracts Different from Grants? Michael Weingarten	3:30 pm
Q&A	3:40 pm
FY2014 Contract Funding Opportunities at NCI Andrew Kurtz and Deepa Narayanan	3:50 pm
Andrew Natiz and Deepa Narayanan	
More Q&A	4:10 pm





The Contracts Process at NCI:


How are SBIR Contracts Different from Grants?

http://sbir.cancer.gov/funding/contracts




NCI SBIR Targeted Contract Solicitations





Contract topics in NCI priority areas with strong potential for commercial success



NCI SBIR contracts (thousands)

% of total NCI SBIR

SBIR Contracts vs. Grants



	SBIR Grants	SBIR Contracts
Scope of the proposal	Investigator-defined within the mission of NIH	Defined (narrowly) by the NIH
Questions during solicitation period?	May speak with any Program Officer	MUST contact the contracting officer [eshanahan@mail.nih.gov]
Receipt Dates	3 times/year for Omnibus	Only ONCE per year
Reporting	One final report (Phase I); Annual reports (Phase II)	Kickoff presentation, quarterly progress reports, final report, commercialization plan
Set-aside funds for particular areas?	No	Yes
Program Staff Involvement	Low	High

SBIR Contracts vs. Grants



	SBIR Grants	SBIR Contracts	
Peer Review Locus	NIH Center for Scientific Review (CSR)	NCI Division of Extramural Activities (DEA)	
Review Sections	Sections review applications for different programs in similar topic areas	Specific sections for each single topic	
Basis for Award	Peer review score Program relevance & balance	Peer review score Program relevance & balance Negotiation of technical deliverables Budget	
Fast Track	Ph I & II are considered as a single application with a single score	Ph I & II are considered separate proposals; they are reviewed and scored independently	

Contract Review Criteria



Phase I Technical Evaluation Criteria	Weight
 1. The soundness and technical merit of the proposed approach based on: a. Clear measureable goals (milestones) that have a reasonable chance of meeting the topic objective in Phase I; b. The approach is innovative and not routine, c. Offeror's ability to implement technical approach 	40%
2. The qualifications of the proposed PDs/PIs	20%
3. The potential of the proposed research for technological innovation .	15%
 4. The potential of the proposed research for commercial application. The commercial potential of a proposal will be assessed using the following criteria: a. Whether the outcome of the proposed research activity will likely lead to a marketable product or process. b. The offeror's discussion of the potential barriers to entry and the competitive market landscape as well as method to overcome. 	15%
5. The adequacy and suitability of the facilities and research environment	10%

See pg. 26 of PHS2014-1 for more details about the evaluation process

Contract Review Criteria



For Fast-Track proposals: Phase II Technical Evaluation Criteria	Weight
 1. The soundness and technical merit of the proposed approach based on: a. Clear measureable goals (milestones) that have a reasonable chance of meeting the topic objective in Phase II; b. The approach is innovative and not routine, c. Offeror's ability to implement technical approach 	30%
 2. The potential of the proposed research for commercial application, as documented in the Commercialization Plan and evidenced by: a. Offeror's record of successfully commercializing prior SBIR/STTR or other research projects b. Commitments of additional investment during Ph I & Ph III from private sector or other non-SBIR funding sources c. Other indicators of commercial potential for the proposed research 	30%
3. The qualifications of the proposed PDs/PIs , supporting staff and consultants.	25%
4. The adequacy and suitability of the facilities and research environment	15%

See pg. 26 of PHS2014-1 for more details about the evaluation process Amendment has updated weights

http://grants.nih.gov/grants/guide/notice-files/NOT-OD-14-013.html

Agenda



Welcome Jennifer Shieh	3:00 pm	
Overview of the NCI SBIR/STTR Programs Michael Weingarten	3:05 pm	
What Does It Take to Get Awarded? Tips on Submitting a Proposal Michael Weingarten	3:15 pm	
The Contracts Process at NCI: How are SBIR Contracts Different from Grants? Michael Weingarten	3:30 pm	
Q&A	3:40 pm	
FY2014 Contract Funding Opportunities at NCI Andrew Kurtz and Deepa Narayanan	3:50 pm	
More Q&A	4:10 pm	
Closing Remarks	4:25 pm	
<mark>ir.cancer.gov/funding/contracts</mark>		

Submit Your Questions



Submit your questions any time via the Q&A box on the right-hand side of your screen.

If you do not see the Q&A box, you can expand it by hovering over the green bar at the top of your screen and clicking the Q&A

button.



Submit Your Questions



Please submit questions of a general nature, with no proprietary information.

We will not answer questions specific to your project in this webinar. Send your questions about:

CONTRACTS to Elizabeth
Shanahan, <u>eshanahan@mail.nih.gov</u> or
GRANTS to <u>NCIsbir@mail.nih.gov</u>

The webinar slides, audio recording, and Q&A will be published to the website, http://sbir.cancer.gov

Agenda



Welcome Jennifer Shieh	3:00 pm
Overview of the NCI SBIR/STTR Programs Michael Weingarten	3:05 pm
What Does It Take to Get Awarded? Tips on Submitting a Proposal Michael Weingarten	3:15 pm
The Contracts Process at NCI: How are SBIR Contracts Different from Grants? Michael Weingarten	3:30 pm
Q&A	3:40 pm
FY2014 Contract Funding Opportunities at NCI Andrew Kurtz and Deepa Narayanan	3:50 pm
More Q&A	4:10 pm
Closing Remarks	4:25 pm
ir cancor gov/funding/contracts	

http://sbir.cancer.gov/funding/contracts





FY 2014 NIH and CDC SBIR Contract Solicitation

http://sbir.cancer.gov/funding/contracts



Funding Opportunity Summary



PHS-2014-1 "HHS, NIH, and CDC SBIR Program Solicitation"

ONE proposal receipt date per year:

Published August 29, 2013; original deadline November 13

EXTENDED

Receipt Date: November 25, 2013, 4:30 PM ET

RFP can be found at:

http://grants.nih.gov/grants/funding/SBIRContract/PHS2014-1.pdf

Amendment: http://grants.nih.gov/grants/guide/notice-files/NOT-OD-14-013.html

More info about NCI's topic areas:

http://sbir.cancer.gov/funding/contracts/

NCI Contract Topics for FY14



http://sbir.cancer.gov/funding/contracts

Therapy & Diagnosis

- 326 Development of Novel Therapeutic Agents that Target Cancer Stem Cells
- 327 **Reformulation** of Failed Chemotherapeutic Drugs
- 331 Development of a Biosensor-Based Core Needle Tumor Biopsy Device
- 332 Development of Radiation Modulators for Use During Radiotherapy

Advancing Cancer Research

- 328 Validation of 3D Human Tissue Culture Systems that Mimic the Tumor Microenvironment
- 329 Proteomic Analysis of Single Cells Isolated from Solid Tumors
- 330 Generation of Site-Specific Phopho-Threonine Protein Standards for Use in Cancer Assays

Health IT

• 333 **Software Tools** for the Development of Environmental Measures Related to Cancer Health Behavior and Resources

Topic 326: Development of Novel Therapeutic Agents that Target Cancer Stem Cells



Budget: Phase I \$225,000 for 9 months; Phase II \$1.5M for 2 years

Number of Anticipated Awards: 3 – 5

Fast-Track proposals **not** accepted.

Goal: Development of novel therapeutic agents that target cancer stem cells (CSCs), CSC-related biomarkers, or CSC pathways that affect fundamental processes associated with carcinogenesis, tumor progression, maintenance, recurrence or metastasis. Emphasis is placed on agents that target CSC self-renewal, regeneration, or differentiation processes.

- Demonstrate in vitro efficacy for the agent(s) that targets CSCs.
- Validate effect of the agent(s) on CSCs.
- Conduct structure-activity relationship (SAR) studies, medicinal chemistry, and/or lead antibody optimization.
- Perform animal toxicology and pharmacology studies as appropriate for the agent(s) selected for development.
- Develop a detailed experimental plan (to be pursued under a future SBIR Phase II award) necessary for filing an IND or an exploratory IND.

Topic 327: Reformulation of Failed Chemotherapeutic Drugs



Budget: Phase I \$225,000 for 9 months; Phase II \$1.5M for 2 years

Number of Anticipated Awards: 2 – 4

Fast-Track proposals accepted.

Goal: Reformulation of small-molecule chemotherapeutic agents that have failed previously in pre-clinical development or in human clinical trials.

Approaches that are NOT accepted under this topic:

- Chemical entities that have received FDA approval for any indication (cancer or otherwise).
- Chemically-modified, failed chemotherapeutic agents (i.e. traditional medicinal chemistry approaches are considered non-responsive).

- Identification of appropriate cancer indication(s) for proposed reformulated drug, and detailed experimental strategy
- Proof-of-concept attachment, encapsulation, or incorporation of the candidate chemotherapeutic agent to the delivery vehicle
- Proof-of-concept small animal studies demonstrating therapeutic efficacy and improved therapeutic index, bioavailability, etc. compared to use of free drug

Topic 328: Validation of 3D Human Tissue Culture

Budget: Phase I \$225,000 for 9 months; Phase II \$1.5M for 2 years

Number of Anticipated Awards: 5 – 7

Fast-Track proposals accepted.

Goal: Validation of 3D human tissue model culture systems that accurately mimic the tumor microenvironment using anti-cancer agents with known effects, to demonstrate the system's utility as a predictive tool, pre-clinical screening assay, and/or chemosensitivity assay.

Essential features include:

- Multicellular architecture representing physiologically relevant characteristics
- Ability to examine multiple aspects of cancer, such as tumor growth, angiogenesis, etc.
- Compatibility with high content screening platforms that include multiple molecular readouts, such as genomic, proteomic, metabolomic, or epigenomic analyses.

- Validate a reproducible 3D culture that mimics the tumor microenvironment and appropriate preclinical or chemo-sensitivity assays to screen response to therapeutics
- Specify metrics used and criteria for prediction of clinical efficacy prior to demonstration of accurate prediction of clinical efficacy.
- Demonstrate accurate prediction of clinical efficacy or chemo-sensitivity in the culture system using at least one anti-cancer agent with known clinical profile.
- Benchmark performance against 2D and currently available 3D culture systems.

Topic 329: Proteomic Analysis of Single Cells Isolated from Solid Tumors



Budget: Phase I \$160,000 for 9 months; Phase II \$1M for 2 years

Number of Anticipated Awards: 4

Fast-Track proposals accepted.

Goal: Advance field of single cell proteomics through optimization of single cell isolation from tumors, and the validation and benchmarking of proteomic analytical methods.

Phase I Activities & Deliverables Include:

- Build cell isolation prototype
- Demonstrate proof-of-concept functionality using solid tumor clinical samples for proteomic analysis applications
- Establish a protocol to integrate single cell isolation technique into a proteomic platform, such as mass spectrometry

- Demonstrate medium to high-throughput single cell isolation capacity of the prototype and integrate all modules in the proteomic platform.
- Benchmark system by comparing and contrasting competitive advantage of prototype.

Topic 330: Generation of Site-Specific Phospho-Threonine Protein Standards for Use in Cancer Assays



Budget: Phase I \$150,000 for 9 months; Phase II \$1M for 2 years

Number of Anticipated Awards: 3 – 5

Fast-Track proposals accepted.

Goal: Development of site-directed phospho-threonine protein synthesis technologies for the production of pThr protein/polypeptide standards.

Phase I Activities & Deliverables Include:

- Develop proof-of-concept methodology to reliably produce threonine sitedirected, high content (>50%), pThr-protein/polypeptide standards for at least 2 NCI-approved targets
- Demonstrate reproducibility & accuracy of methodology
- Demonstrate preliminary product stability

- Optimization of process to reproducibly generate quantitative, threonine sitespecific phosphorylation for six NCI-approved targets
- Perform full validation of method

Topic 331: Development of a Biosensor-Based Core Needle Tumor Biopsy Device



Budget: Phase I \$225,000 for 9 months; Phase II \$1.5M for 2 years

Number of Anticipated Awards: 3 – 5

Fast-Track proposals accepted.

Goal: Advance development of biopsy needle-based biosensor technology that can determine regions of maximum tumor cellularity within a biopsy region.

Phase I Activities & Deliverables Include:

- Manufacture and optimize needle-based biosensor device featuring:
 - Adaptibility for use with existing imaging/ultrasound needle placement methods & needle biopsy procedures
 - Real-time signal generation distinguishing between tumor & non-tumor tissue
 - Demonstration of not damaging or changing tissue biology surrounding needle placement
- Show preliminary proof-of-concept of sensor-guided biopsy in relevant animal model

- Demonstrate feasibility of technique to complement current procedures
- Demonstrate performance of the device as designed and intended in relevant clinical veterinary models

Topic 332: Development of Radiation Modulators for Use During Radiotherapy*



Budget: Phase I \$200,000 for 9 months; Phase II \$1.5M for 2 years

Number of Anticipated Awards: 3 – 5

Fast Track proposals accepted.

Goal: Development of radiosensitizers, radioprotectants, or radiomitigators that decrease normal tissue injury and/or enhance tumor killing.

Phase I Activities & Deliverables Include:

- In vitro testing
- Clonogenic survival studies
- Preliminary in vivo toxicity studies

- In vivo experiments
- PK/PD in rodent model
- GMP drug production/sourcing
- IND approval

Topic 333: Software Tools for the Development of Environmental Measures Related to Cancer Health Behaviors and Resources



Budget: Phase I \$200,000 for 9 months; Phase II \$1M for 2 years

Number of Anticipated Awards: 2 – 3

Fast Track proposals accepted.

Goal: To support the development of an efficient, user-centered software tool that connects diverse data sources to enable the creation of metrics describing the environment related to health behaviors and services.

Phase I Activities & Deliverables Include:

- Establish project team with broad expertise
- Prototype that facilitates use of existing APIs with salient data sources, allows import and export of data to and from existing tabular datasets, uses geographic identifiers compatible with major GIS software

- Beta-test and finalize:
 - methods for combining data into candidate metrics.
 - Develop, beta-test, and finalize data integration and visualization tools developed in Phase I
- Conduct usability testing



Questions About Contracts?

Ms. Elizabeth Shanahan

eshanahan@mail.nih.gov

240.276.5432

http://sbir.cancer.gov/funding/contracts/

Agenda



Welcome Jennifer Shieh	3:00 pm		
Overview of the NCI SBIR/STTR Programs Michael Weingarten	3:05 pm		
What Does It Take to Get Awarded? Tips on Submitting a Proposal Michael Weingarten	3:15 pm		
The Contracts Process at NCI: How are SBIR Contracts Different from Grants? Michael Weingarten	3:30 pm		
Q&A	3:40 pm		
FY2014 Contract Funding Opportunities at NCI Andrew Kurtz and Deepa Narayanan	3:50 pm		
More Q&A	4:10 pm		
Closing Remarks	4:25 pm		
http://sbir.cancer.gov/funding/contracts			

Submit Your Questions



Submit your questions any time via the Q&A box on the right-hand side of your screen.

If you do not see the Q&A box, you can expand it by hovering over the green bar at the top of your screen and clicking the Q&A

button.



Submit Your Questions



Please submit questions of a general nature, with no proprietary information.

We will not answer questions specific to your project in this webinar. Send your questions about:

CONTRACTS to Elizabeth
Shanahan, <u>eshanahan@mail.nih.gov</u> or
GRANTS to <u>NCIsbir@mail.nih.gov</u>

The webinar slides, audio recording, and Q&A will be published to the website, http://sbir.cancer.gov

Agenda



	Welcome Jennifer Shieh	3:00 pm
	Overview of the NCI SBIR/STTR Programs Michael Weingarten	3:05 pm
	What Does It Take to Get Awarded? Tips on Submitting a Proposal Michael Weingarten	3:15 pm
	The Contracts Process at NCI: How are SBIR Contracts Different from Grants? Michael Weingarten	3:30 pm
	Q&A	3:40 pm
	FY2014 Contract Funding Opportunities at NCI Andrew Kurtz and Deepa Narayanan	3:50 pm
	More Q&A	4:10 pm
	Closing Remarks	4:25 pm
http://sbir.cancer.gov/funding/contracts		





NCI SBIR Development Center

NCIsbir@mail.nih.gov

Phone: 240.276.5300

http://sbir.cancer.gov

Sign up for updates!

Follow us on Twitter @NCIsbir

